In last trading session, Celldex Therapeutics Inc. (NASDAQ:CLDX) saw 1.19 million shares changing hands with its beta currently measuring 3.05. Company’s recent per share price level of $27.78 trading at -$0.22 or -0.79% at ring of the bell on the day assigns it a market valuation of $1.08B. That closing price of CLDX’s stock is at a discount of -19.65% from its 52-week high price of $33.24 and is indicating a premium of 65.48% from its 52-week low price of $9.59. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.42 million shares which gives us an average trading volume of 588.13K if we extend that period to 3-months.
For Celldex Therapeutics Inc. (CLDX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Celldex Therapeutics Inc. (NASDAQ:CLDX) trade information
Upright in the red during last session for losing -0.79%, in the last five days CLDX remained trading in the red while hitting it’s week-highest on Monday, 06/14/21 when the stock touched $27.78 price level, adding 10.85% to its value on the day. Celldex Therapeutics Inc.’s shares saw a change of 58.56% in year-to-date performance and have moved -10.50% in past 5-day. Celldex Therapeutics Inc. (NASDAQ:CLDX) showed a performance of 2.89% in past 30-days. Number of shares sold short was 3.22 million shares which calculate 7.21 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $34.67 to the stock, which implies a rise of 19.87% to its current value. Analysts have been projecting $33.00 as a low price target for the stock while placing it at a high target of $36.00. It follows that stock’s current price would drop -29.59% in reaching the projected high whereas dropping to the targeted low would mean a loss of -18.79% for stock’s current value.
Celldex Therapeutics Inc. (CLDX) estimates and forecasts
Statistics highlight that Celldex Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 47.45% of value to its shares in past 6 months, showing an annual growth rate of 10.00% while that of industry is 9.10. Apart from that, the company came raising its revenue forecast for fiscal year 2021. This year revenue growth is estimated to fall -48.10% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $685k for the same. And 2 analysts are in estimates of company making revenue of $960k in the next quarter that will end on Jun 2021.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 36.60% during past 5 years.
Celldex Therapeutics Inc. is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Celldex Therapeutics Inc. (NASDAQ:CLDX)’s Major holders
Insiders are in possession of 5.26% of company’s total shares while institution are holding 88.77 percent of that, with stock having share float percentage of 93.69%. Investors also watch the number of corporate investors in a company very closely, which is 88.77% institutions for Celldex Therapeutics Inc. that are currently holding shares of the company. RTW Investments LP is the top institutional holder at CLDX for having 3.91 million shares of worth $80.52 million. And as of Mar 30, 2021, it was holding 9.87% of the company’s outstanding shares.
The second largest institutional holder is Redmile Group, LLC, which was holding about 3.39 million shares on Mar 30, 2021. The number of shares represents firm’s hold over 8.55% of outstanding shares, having a total worth of $69.79 million.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 30, 2020, the former fund manager was holding 1.84 million shares of worth $32.19 million or 4.64% of the total outstanding shares. The later fund manager was in possession of 1.79 million shares on Mar 30, 2021, making its stake of worth around $36.79 million in the company or a holder of 4.51% of company’s stock.